They reported that the concentration of GLAST+ EVs in plasma, as measured by nanoparticle tracking analysis, was higher in controls than in individuals with MS, while L1CAM+ EVs did not differ between them. The gene discussed is L1CAM; the disease is myeloid sarcoma.